Recap: Recro Pharma Q4 Earnings
Recro Pharma (NASDAQ:REPH) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Biomerica (NASDAQ:BMRA) stock increased by 10.2% to $4.95 during Wednesday's after-market session. The market value of their outstanding shares is at $61.9 million. As per the news, the Q2 earnings report came out today.
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Recro Pharma Q3 EPS $(0.07), Inline, Sales $18.24M Beat $18.07M Estimate
Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year. The
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
William Blair Initiates Coverage On Recro Pharma with Outperform Rating
William Blair analyst John Kreger initiates coverage on Recro Pharma (NASDAQ:REPH) with a Outperform rating.
Recro Pharma’s Return On Capital Employed Overview
According to Benzinga Pro, during Q2, Recro Pharma (NASDAQ:REPH) earned $1.84 million, a 164.34% increase from the preceding quarter. Recro Pharma also posted a total of $18.02 million in sales, a 7.22% increase since Q1.
